NMDA/glutamate mechanism of magnesium-induced anxiolytic-like behavior in mice

Pharmacological Reports

Volumn 60, Issue 5, 2008, Pages 655-663

  Poleszak, Ewa ^a   Wlaź, Piotr ^b   Wróbel, Andrzej ^a   Fidecka, Sylwia ^a   Nowak, Gabriel ^c,d  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Anxiety; Elevated plus maze; Magnesium; Mice; NMDA receptor ligands

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; ANXIOLYTIC AGENT; CYCLOSERINE; DIZOCILPINE; GLUTAMATE RECEPTOR; GLYCINE; L 701 324; MAGNESIUM ASPARTATE; N METHYL DEXTRO ASPARTIC ACID; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY DISORDER; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE; DRUG POTENTIATION; MAZE TEST; MONOTHERAPY; MOUSE; NONHUMAN; TRANQUILIZING ACTIVITY;

EID: 57849115312     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Anthony EW, Nevins ME: Anxiolytic-like effects of N-methyl-D-aspartate-associated glycine receptor ligands in the rat potentiated startle test. Eur J Pharmacol, 1993, 250, 317-324.
2. Boyce-Rustay JM, Holmes A: Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology, 2006, 31, 2405-2414.
3. Decollogne S, Tomas A, Lecerf C, Adamowicz E, Seman M: NMDA receptor complex blockade by oral administration of magnesium: comparison with MK-801. Pharmacol Biochem Behav, 1997, 58, 261-268.
4. 1A receptor agonist and NMDA receptor antagonist in the social interaction test and the elevated plus maze. Eur J Pharmacol, 1989, 169, 1-10.
5. Emmett MR, Mick SJ, Cler JA, Rao TS, Iyengar S, Wood PL: Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology, 1992, 30, 1167-1171.
6. 2+: an endogenous modulator of ligand- and voltage-gated ion channels. Neuropharmacology, 1994, 33, 935-952.
7. Hasey GM, D'Alessandro E, Cooke RG, Warsh JJ: The interface between thyroid activity, magnesium, and depression: a pilot study. Biol Psychiatry, 1993, 33, 133-135.
8. Heiden A, Frey R, Presslich O, Blasbichler T, Smetana R, Kasper S: Treatment of severe mania with intravenous magnesium sulphate as a supplementary therapy. Psychiatry Res, 1999, 3, 239-246.
9. Hood WF, Compton RP, Monahan JB: D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett, 1989, 98, 91-95.
10. Johnson JW, Ascher P: Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature, 1987, 325, 529-531.
11. Karcz-Kubicha M, Jessa M, Nazar M, Płaźnik A, Hartman S, Parsons CG, Danysz W: Anxiolytic activity of glycine-B antagonists and partial agonists - no relation to intrinsic activity in the patch clamp. Neuropharmacology, 1997, 36, 1355-1367.
12. Kessler RC, Ustun TB: The world mental health (WMH) suryey initiative version of the world health-organization (WHO) composite international diagnostic interview (CIDI). Int J Methods Psychiatr Res, 2004, 13, 93-121.
13. Kirov GK, Tsachev KN: Magnesium, schizophrenia and manic-depressive disease. Neuropsychobiology, 1990, 23, 79-81.
14. Kotlińska J, Liljequist S: A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L-701,324. Psychopharmacology, 1998, 135, 175-181.
15. Kroczka B, Brański P, Pałucha A, Pilc A, Nowak G: Antidepressant-like properties of zinc in rodent forced swim test. Brain Res Bull, 2001, 55, 297-300.
16. Kroczka B, Zieba A, Dudek D, Pilc A, Nowak G: Zinc exhibits an antidepressant-like effects in the forced swiming test in mice. Pol J Pharmacol, 2000, 52, 403-406.
17. Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman RM, Charney DS, Abi-Saab W, Madonick S: NMDA agonist and antagonist as probes of glutamergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry, 1999, 7, 125-143.
18. Lipman JJ, Spencer PS: Repid intracerebroventricular injection assisted by an automatic syringe. J Pharmacol Methods, 1980, 4, 327-333.
19. Lister RG: The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology, 1987, 92, 180-185.
20. MacKinnon GL, Parker WA: Benzodiazepine withdrawal syndrome: a literature review and evaluation. Am J Drug Alcohol Abuse, 1982, 9, 19-33.
21. Monaghan DT, Bridges RJ, Cotman CW: The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol, 1989, 29, 365-402.
22. 3H]glycine recognition site as a modulatory site of the N-methyl-D-aspartate receptor complex. J Neurochem, 1989, 53, 370-375.
23. Murck H: Magnesium and affective disorders. Nutr Neurosci, 2002, 5, 375-389.
24. Nowak G, Szewczyk B, Wierońska JM, Brański P, Pałucha A, Pilc A, Sadlik K, Piekoszewski W: Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull, 2003, 61, 159-164.
25. Novak L, Bregestowski P, Ascher P, Herbet A, Prochiantz A: Magnesium gates glutamate-activated channels in mouse central neurons. Nature, 1984, 307, 462-465.
26. Pellow S, Chopin P, File SE, Briley M: Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods, 1985, 14, 149-167.
27. Pellow S, File SE: Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav, 1986, 24, 525-529.
28. Pillay NS, Stein D: Emerging anxiolytics. Expert Opin Emerg Drugs, 2007, 12, 541-554.
29. Płaźnik A, Pałejko W, Nazar M, Jessa M: Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur Neuropsychopharmacol, 1994, 4, 503-512.
30. A receptors are involved in magnesium-induced anxiolytic-like behavior in mice. Pharmacol Rep, 2008, 60, 483-489.
31. Poleszak E: Modulation of antidepressant-like activity of magnesium by serotonergic system. J Neural Transm, 2007, 114, 1129-1134.
32. Poleszak E, Szewezyk B, Kedzierska E, Wlaź P, Pilc A, Nowak G: Antidepressant- and anxiolytic-like activity of magnesium in mice. Pharmacol Biochem Behav, 2004, 78, 7-12.
33. Poleszak E, Wlaź P, Kedzierska E, Nieoczym D, Wróbel A, Fidecka S. Pilc A. Nowak G: NMDA/glutamate mechanism of antidepressant-like action of magnesium in forced swim test in mice. Pharmacol Biochem Behav, 2007, 88, 158-164.
34. Poleszak E, Wlaź P, Kedzierska E, Nieoczym D, Wyska E, Szymura-Oleksiak J, Fidecka S et al.: Immoblility stress induces depression-like behavior in the forced swim test in mice: effect of magnesium and imipramine. Pharmacol Rep, 2006, 58, 746-752.
35. Poleszak E, Wlaź P, Kedzierska E, Radziwoń-Zaleska M, Pilc A, Fidecka S, Nowak G: Effects of acute and chronic treatment with magnesium in the forced swim test in rats. Pharmacol Rep, 2005, 57, 654-658.
36. Poleszak E, Wlaź P, Szewczyk B, Kedzierska E, Wyska E, Librowski T, Szymura-Oleksiak J et al.: Enhancement of antidepressant-like activity by joint administration of imipramine and magnesium in the forced Swim test: behavioral and pharmacokinetic studies in mice. Pharmacol Biochem Behav, 2005, 81, 524-529.
37. Poleszak E, Wlaź P, Wróbel A, Dybała M, Sowa M, Fidecka S, Pilc A, Nowak G: Activation of the NMDA/glutamate receptor complex antagonizes the NMDA antagonist-induced antidepressant-like effects in the forced swim test. Pharmacol Rep, 2007, 59, 595-600.
38. Przegaliński E, Tatarczyńska E, Chojnacka-Wójcik E: Anxiolytic- and antidepressant-like effects of an antagonist at glycine B receptors. Pol J Pharmacol, 1998, 50, 349-354.
39. Przegaliński E, Tatarczyńska E, Chojnacka-Wójcik E: The influenee of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. Neuropsychopharmacology, 2000, 39, 1858-1864.
40. Reynolds IJ, Miller RJ: Multiple sites for the regulation of the N-methyl-D-aspartate receptor. Mol Pharmacol, 1988, 33, 581-584.
41. 2+. J Neurochem, 62, 1994, 916-922.
42. Seelig MS: Consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications (a review). J Am Coll Nutr, 1994, 13, 429-446.
43. Seelig MS, Berger AR, Spielholsz N: Latent tetany and anxiety, marginal magnesium deficit, and normocalcemia. Dis Nerv Syst, 1975, 36, 461-465.
44. Sharma AC, Kulkarni SK: Evidence for benzodiazepine receptor interaction with MK-801 in anxiety related behaviour in rats. Indian J Exp Biol, 1993, 31, 191-193.
45. Singewald N, Sinner C, Hetzenauer A, Saroti SB, Murek H: Magnesium-deficient diet alters depression- and anxiety-related behavior in mice-influence of desipramine and Hypericum perforatum extract. Neuropharmacology, 2004, 47, 1189-1197.
46. Skolnick P: Antidepressants for the new millennium. Eur J Pharmacol, 1999, 375, 31-40.
47. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R: Adaptation of N-methyl-D-aspartate receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry, 1996, 29, 23-26.
48. Skolnick P, Legutko B, Li X, Bymaster FP: Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol Res, 2001, 43, 411-422.
49. Stahl SM: Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry, 2002, 63, 756-757.
50. Steward SH, Westra HA: Benzodiazepine side-effects: from the bench to the clinic. Curr Pharm Des, 2002, 8, 1-3.
51. Tricklebank MD, Singh L, Oles RJ, Preston C, Iversen SD: The behavioral effects of MK-801: a comparison with antagonists acting non-competitively at the NMDA receptor. Eur J Pharmacol, 1989, 167, 127-135.
52. Trullas R, Folio T, Young A, Miller R, Boje K, Skolnick P: 1-Aminocyclopropanecarboxylates exhibit anti-depressant and anxiolytic action in animal models. Eur J Pharmacol, 1991, 203, 379-385.
53. Trullas R, Jackson B, Skolnick P: Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnine-insensitive glycine receptors. Pharmacol Biochem Behav, 1989, 34, 313-316.
54. Trullas R, Skolnick P: Functional antagonists at the NMDA receptor complex exhibit antidepressant action. Eur J Pharmacol, 1990, 185, 1-10.
55. 2+ block of the N-methyl-D-aspartate receptor channel. J Gen Physiol, 2001, 117, 275-286.
56. Willets J, Balster RL, Leander JD: The behavioral pharmacology of NMDA receptor antagonist. Trends Pharmacol Sci, 1990, 11, 423-428.